BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
BIOMARIN PHARMACEUTICAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$54.67−0.01 (-0.02%)
Close on Oct 19, 2026
- Market cap
- $10.63B
- P/E (TTM)
- 143.9
- Dividend yield
- –
BIOMARIN PHARMACEUTICAL INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product revenues | $984.39M | $760.08M | $859.32M | $760.81M | $812.98M | $734.64M | $735.63M | $733.87M | $702.13M | $637.82M | $633.15M | $568.27M | 99.5% | +21.1% |
| VOXZOGO | $252.53M | $219.88M | $273.39M | $218.39M | $221.39M | $213.75M | $208.50M | $189.79M | $183.92M | $152.89M | $145.74M | $122.97M | 25.5% | +14.1% |
| VIMIZIM | $194.37M | $210.20M | $205.53M | $182.76M | $215.42M | $188.35M | $191.09M | $178.16M | $178.02M | $192.52M | $175.60M | $158.87M | 19.6% | -9.8% |
| NAGLAZYME | $135.26M | $130.07M | $120.22M | $122.03M | $128.87M | $114.29M | $110.00M | $131.91M | $132.05M | $105.63M | $98.25M | $108.92M | 13.7% | +5.0% |
| PALYNZIQ | $135.17M | $89.56M | $125.33M | $108.78M | $105.94M | $93.27M | $100.41M | $90.63M | $88.29M | $75.71M | $87.81M | $78.89M | 13.7% | +27.6% |
| GALAFOLD | $105.75M | – | – | – | $0 | – | – | – | – | – | – | – | 10.7% | – |
| BRINEURA | $51.37M | $47.10M | $49.39M | $47.95M | $48.69M | $40.36M | $47.72M | $37.01M | $45.31M | $39.05M | $43.65M | $41.04M | 5.2% | +5.5% |
| ALDURAZYME | $43.54M | $36.74M | $49.39M | $53.71M | $56.44M | $48.98M | $39.04M | $71.03M | $38.56M | $35.26M | $42.72M | $13.81M | 4.4% | -22.9% |
| POMBILITI + OPFOLDA | $30.26M | – | – | – | $0 | – | – | – | – | – | – | – | 3.1% | – |
| KUVAN | $24.44M | $23.88M | $23.34M | $24.03M | $27.03M | $25.14M | $28.33M | $28.12M | $28.55M | $35.91M | $36.72M | $42.95M | 2.5% | -9.6% |
| ROCTAVIAN | $11.71M | $2.64M | $12.75M | $3.18M | $9.20M | $10.51M | $10.55M | $7.24M | $7.43M | $849.00K | $2.67M | $822.00K | 1.2% | +27.3% |
| Royalty and other revenues | $5.32M | $6.13M | $15.24M | $15.32M | $12.43M | $10.50M | $11.68M | $11.87M | $9.90M | $11.02M | $13.06M | $13.06M | 0.5% | -57.2% |
| Total enzyme product revenues | – | – | – | – | – | – | – | – | – | – | $448.03M | $401.52M | – | – |
By region
From the segment and revenue-disaggregation notes of Biomarin Pharmaceutical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.